UnitedHealth Group (UNH), CVS Health (CVS), and Cigna (CI) are embroiled in legal disputes across several states, challenging new laws designed to regulate or even break up their vertically integrated pharmacy benefit management (PBM) businesses. These state-level efforts, driven by concerns over PBM influence on drug pricing and market competition, represent a significant challenge to the insurers' current operating models.
The core of the conflict lies in the PBMs' role in negotiating drug prices with manufacturers and managing prescription drug benefits for health plans. Critics argue that the consolidation of PBMs within large insurers creates conflicts of interest and reduces transparency, potentially leading to higher costs for consumers and pharmacies. States like Arkansas and Ohio have passed laws granting more regulatory oversight or even prohibiting PBMs from imposing certain fees or owning pharmacies.
The insurers contend that these state laws are preempted by federal ERISA regulations, which govern employer-sponsored health plans, and that their integrated model drives efficiency and cost savings. The outcomes of these lawsuits will have far-reaching implications, potentially reshaping the competitive landscape of the healthcare and pharmacy sectors. A win for the states could force operational changes or even divestitures, while a win for the insurers would solidify their current structure and business practices.